These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23761225)

  • 1. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.
    Xue L; Rup B
    AAPS J; 2013 Jul; 15(3):893-6. PubMed ID: 23761225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists.
    Xue L; Fiscella M; Rajadhyaksha M; Goyal J; Holland C; Gorovits B; Morimoto A
    AAPS J; 2013 Jul; 15(3):852-5. PubMed ID: 23620231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing Antibody: Biotherapeutic Modality-Based Review.
    Gorovits B; Clements-Egan A; Birchler M; Liang M; Myler H; Peng K; Purushothama S; Rajadhyaksha M; Salazar-Fontana L; Sung C; Xue L
    AAPS J; 2016 Mar; 18(2):311-20. PubMed ID: 26821802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.
    Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B
    AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics.
    Lin J; Lee SL; Russell AM; Huang RF; Batt MA; Chang SS; Ferrante A; Verdino P
    PLoS One; 2021; 16(7):e0254944. PubMed ID: 34297759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk.
    Bivi N; Moore T; Rodgers G; Denning H; Shockley T; Swearingen CA; Gelfanova V; Calderon B; Peterson DA; Hodsdon ME; Siegel RW; Higgs RE; Konrad RJ
    MAbs; 2019 Jul; 11(5):861-869. PubMed ID: 31099718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.
    Xue L; Clements-Egan A; Amaravadi L; Birchler M; Gorovits B; Liang M; Myler H; Purushothama S; Manning MS; Sung C
    AAPS J; 2017 Nov; 19(6):1576-1586. PubMed ID: 29110222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Model-Based Approach to Quantify the Time-Course of Anti-Drug Antibodies for Therapeutic Proteins.
    Ren Y; Li L; Kirshner S; Wang Y; Sahajwalla C; Ji P
    Clin Pharmacol Ther; 2019 Apr; 105(4):970-978. PubMed ID: 30372517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
    Kloks C; Berger C; Cortez P; Dean Y; Heinrich J; Bjerring Jensen L; Koppenburg V; Kostense S; Kramer D; Spindeldreher S; Kirby H
    J Immunol Methods; 2015 Feb; 417():1-9. PubMed ID: 25602137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of Anti-drug Antibody Affinity in Clinical Study Samples Provides a Tool for Evaluation of Immune Response Maturation.
    Joyce A; Shea C; You Z; Gorovits B; Lepsy C
    AAPS J; 2022 Nov; 24(6):114. PubMed ID: 36324032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of anti-drug antibodies in preclinical pharmacokinetic assessment.
    Thway TM; Magana I; Bautista A; Jawa V; Gu W; Ma M
    AAPS J; 2013 Jul; 15(3):856-63. PubMed ID: 23653044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.
    Liao K; Derbyshire S; Wang KF; Caucci C; Tang S; Holland C; Loercher A; Gunn GR
    AAPS J; 2018 Mar; 20(3):51. PubMed ID: 29549534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque.
    Kovalova N; Knierman MD; Brown-Augsburger PL; Wroblewski VJ; Chlewicki LK
    Immunogenetics; 2019 Nov; 71(10):605-615. PubMed ID: 31776588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
    Lotz GP; Benstein K; Bloem K; Buddiger H; Calonder C; Elm S; Fernandez E; Goodman J; Gorovits B; Grudzinska-Goebel J; Janssen M; Jawa V; Kramer D; Luo L; Malisauskas M; Michaut L; Schäfer M; Spindeldreher S; Ullmann M; Nana Weldingh K; Kromminga A; Snoeck V
    AAPS J; 2022 May; 24(3):68. PubMed ID: 35554731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.
    van Schie KA; Wolbink GJ; Rispens T
    MAbs; 2015; 7(4):662-71. PubMed ID: 25962087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.
    Adedokun OJ; Gunn GR; Leu JH; Gargano C; Xu Z; Sandborn WJ; Rutgeerts P; Shankar G
    Inflamm Bowel Dis; 2019 Aug; 25(9):1532-1540. PubMed ID: 30753466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.